reports
MKS Instruments Reports First Quarter 2024 Financial Results
MKS Instruments Reports First Quarter 2024 Financial Results Quarterly revenue of $868 million, above the midpoint of guidanceQuarterly GAAP net income of $15 million and net income per share of $0.22Quarterly Adjusted EBITDA of $217 million and Non-GAAP net earnings per diluted share of $1.18, exceeding the high-end of guidance ANDOVER, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today reported first quarter 2024 financial results. “MKS delivered strong results in the first quarter de...
MKS Instruments Declares Quarterly Cash Dividend
MKS Instruments Declares Quarterly Cash Dividend ANDOVER, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on June 7, 2024, to shareholders of record as of May 28, 2024. Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors. About MKS InstrumentsMKS Instruments enables t...
MKS Receives Samsung Electro-Mechanics (SEMCO) Supplier Excellence Awa...
MKS Receives Samsung Electro-Mechanics (SEMCO) Supplier Excellence Award to Demonstrate Global Competitiveness ANDOVER, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, has been recognized as an outstanding supplier by Samsung Electro-Mechanics (SEMCO), a world-class company that develops and produces major electronics components, for the development and trial production of new products with MKS’ Atotech team in Korea. "This recognition reflects the strong partnership and deep trust that has...
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the first quarter 2024 compared to the first quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2024 was $40.3 million, compared to product revenue, net of $46.8 million in the first quarter of 2023. Based on accounting principles generally accepted in the Un...
Puma Biotechnology to Host Conference Call to Discuss First Quarter 20...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of th...
MKS Instruments Announces First Quarter 2024 Earnings Conference Call
MKS Instruments Announces First Quarter 2024 Earnings Conference Call ANDOVER, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that the Company will release first quarter 2024 financial results after market close on Wednesday, May 8, 2024. A conference call with management will be held on Thursday, May 9, 2024 at 8:30 a.m. (Eastern Time). A live and archived webcast of the call will be available on the company’s website at . To participate in the call by phone, participant...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-...
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Al...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib for the treatment of patients with human epidermal growth factor receptor 2-negative (HER2-negative), hormone receptor-positive metastatic breast cancer in Puma’s Phase II ALISCA-Breast1 trial (Study PUMA-ALI-4201). This trial will investigate alisertib in combination with ...
Moody's revises Zoetis' outlook to positive from stable; affirms Baa1 ...
Moody's Ratings (Moody's) affirmed the ratings of Zoetis Inc. ("Zoetis"), including the Baa1 senior unsecured rating and the Prime-2 commercial paper rating. At the same time, Moody's revised the outlook to positive from stable. The revision in Zoetis' outlook to positive reflects Zoetis continued...
- Valens Research
MOH - Valens Credit Report - 2024 02 27
Cash bond markets are overstating MOH's credit risk with a YTW of 6.033% relative to an Intrinsic YTW of 5.103%, while CDS markets are slightly overstating credit risk with a CDS of 152bps relative to an Intrinsic CDS of 83bps. Furthermore, Moody's is grossly overstating MOH's fundamental credit risk with its highly speculative Ba3 credit rating eight notches below Valens' IG3+ (A1) credit rating. Incentives Dictate BehaviorTM analysis highlights mostly negative signals for credit holders. As a...
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2023 compared to the fourth quarter and full year 2022. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net for the fourth quarter of 2023 was $53.2 million, compared to $53.7 million in the fourth quarter of 2022. Product revenue, net for the full year ...
MKS Instruments Receives 2023 Outstanding Service Award from MFLEX
MKS Instruments Receives 2023 Outstanding Service Award from MFLEX ANDOVER, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (Nasdaq: MKSI), a global provider of technologies that transform our world, recently received the 2023 Outstanding Service Award from MFLEX, a global leader in flexible printed circuit board manufacturing and assembly. The award recognizes MKS for outstanding customer support and system service in high-production manufacturing environments. “We are honored to be recognized by MFLEX for our strong Service capabilities,” said John T.C. Lee, Presid...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 26, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
STT STATE STREET CORPORATION
C CITIGROUP INC.
XNCR XENCOR INC.
XBIT XBIOTECH
TRIP TRIPADVISOR INC.
PSX PHILLIPS 66
POST POST HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PBYI PUMA BIOTECHNOLOGY INC.
MCY MERCURY GENERAL CORPORATION
ISRG INTUITIVE SURGICAL INC.
IRM IRON MOUNTAIN INC.
HOLX HOLOGIC INC.
HMST HOMESTREET INC.
FRPT FRESHPET INC
ENSG ENSIGN GROUP INC.
DY DYCOM INDUSTRIES INC.
DVA DAVITA INC.
CRY CRYOLIFE INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ACGL ARCH CAPITAL GROUP LTD.
CW CURTISS-WRIGHT CORPORATION
MPC. MADISON PACIFIC PROPERTIES INC. CL B
ATRO ASTRONICS CORPORATION
ALPN ALPINE IMMUNE SCIENCES
TNDM TANDEM DIABETES CARE
ABT ABBOTT LABORATORIES
COOP MR. COOPER GROUP INC.
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PFC PREMIER FINANCIAL CORP
OGN ORGANON & CO
2VZ ONTO INNOVATION INC.
FIHL LEONARDO DRS INC.
FIDELIS INSURANCE HOLDINGS LIMITED
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s ...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend TD Cowen’s 44th Annual Health Care Conference, which will be held March 4 – 6, 2024, at the Boston Marriott Copley Place in Boston. Mr. Auerbach will participate in a Breast & Lung Cancer Corporate Panel Discussion on March 6 at 9:10 a.m. ET. A live webcast of the Breast & Lung Cancer Corporate Panel Discussion will be available at , and a replay will be available on Puma’s website f...
Molina Healthcare Inc: 1 director
A director at Molina Healthcare Inc sold 1,000 shares at 401.050USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.